New York, New York--(Newsfile Corp. - June 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS)("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February 8, 2019 initial public offering. . You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Southern District of California. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis' oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
If you suffered a loss in Gossamer you have until June 2, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56987